High grade osteosarcoma of the extremities with lung metastases at presentation: Treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions
Article first published online: 15 SEP 2008
Copyright © 2008 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 98, Issue 6, pages 415–420, 1 November 2008
How to Cite
Bacci, G., Rocca, M., Salone, M., Balladelli, A., Ferrari, S., Palmerini, E., Forni, C. and Briccoli, A. (2008), High grade osteosarcoma of the extremities with lung metastases at presentation: Treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J. Surg. Oncol., 98: 415–420. doi: 10.1002/jso.21140
- Issue published online: 24 OCT 2008
- Article first published online: 15 SEP 2008
- Manuscript Accepted: 24 JUL 2008
- Manuscript Received: 9 FEB 2008
- bone sarcoma;
- pulmonary metastases;
Background and Methods
Between 1986 and 2001, 162 patients with extremity osteosarcoma and lung metastases at presentation, were treated by neoadjuvant chemotherapy, simultaneous resection of primary and, when feasible, secondary lesions followed by chemotherapy.
After neoadjuvant chemotherapy, metastases disappeared in 14 patients, 16 were judged unresectable by both our thoracic surgeons, 132 had primary tumors and lung metastases removed simultaneously. Removal of lung metastases was complete in 123 and incomplete in 9. Histologically lesions were benign in 32 patients. For the 100 patients simultaneously operated with histologically proven lung metastases, 5-year event-free survival (EFS) was 18.9%; 27.4% for the 91 who had a complete resection of pulmonary lesions and entered remission as opposed to none for 9 patients who had incomplete removal of lung nodules. Among these 91, 5-year EFS was significantly higher for patients with monolateral compared to bilateral lesions (27.1% vs. 7.9%, P < 0.02) and when only one to three metastatic nodules were present (40.0% vs. 13.3%, P < 0.0001).
These different results, demonstrate that our treatment had a reasonable survival outcome whereas other groups continue to have dismal prognosis. More efforts should be made to improve survival by identifying new active agents or novel approaches with cellular molecular targets. J. Surg. Oncol. © 2008 Wiley-Liss, Inc.